20% to 40% patients are partial or non responders;
there is a 3-4 week delay before treatments start bringing benefits;
there are systematic, serious side effects (“serotonin syndrom”, mania/hypomania, bleeding, nausea, …);
50% patients discontinue treatment within 6 months because of side effects;
10% patients commit suicide!
they regulate monoamines neurotransmission (SSRIs, SNRIs).
The DEPSTER project, designed and piloted by MAPREG, made the awaited first original proof of concept to relieve depressive situation in relevant animal models.
Now Phase 2 clinical trial is about to be launched.
In 3 different animal models of depressive disorder, MP4343*:
*MAP4343 was systematically compared to PROZAC, and proves better in all outcomes.
Brain inherently ages and becomes slower, subject to failure of memory with correlative loss of self-confidence and desire to act. MAP4343 pharmacological profile allows to propose it as a safe drug to help people fight their cognitive impairments as well as mood disorders.
CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.